
|Articles|July 1, 2002
Intravitreal triamcinolone for AMD appears promising, but more studies needed
Author(s)Laszlo Dosa
Fort Lauderdale, FL-Intravitreal triamcinolone appears to inhibit the growth of choroidal neovascularization (CNV) and reduce subretinal fluid in the short term, but it needs further evaluation, ac-cording to Mark Gillies, MB, BS, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Alcon raises offer in amended deal to acquire STAAR Surgical
2
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
3
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
4
Study maps thermal dynamics of glaucoma laser treatments
5














































.png)


